Applied Molecular Transport Announces Board Appointments

John W. Smither appointed to its board of directors and appointed chairman of the audit committee

Graham K. Cooper Named Executive Chairman

Helen S. Kim appointed Independent Lead Director

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of John W. Smither to its Board of Directors and Chairman of its Audit Committee. AMT also announced that current director Graham K. Cooper has been named executive chairman and current director Helen S. Kim has been named senior independent director.

“We are thrilled to have John join AMT’s Board of Directors,” said Tahir Mahmood, Ph.D., Chairman and CEO and Co-Founder of AMT. “John is a recognized industry leader whose extensive experience in financial and business strategy will be instrumental as we anticipate four major Phase 2 data reads for Oral AMT-101 this year, in addition to advancing our transformative pipeline of novel biological therapies.”

Dr Mahmood continued: “I am also delighted to have Graham take on the role of Executive Chairman and Helen to take on the role of Independent Lead Director. Both Graham and Helen have been invaluable members of AMT’s Board of Directors and their immense experience in our field will continue to be essential to AMT’s future growth. I look forward to working alongside Graham as we grow AMT.

Mr. Smither added, “I am delighted to join AMT’s Board of Directors in such an important year for the company. I look forward to contributing to the future success of AMT and working with the other members of the Board of Directors, as AMT continues to realize its vision to deliver novel oral biologic product candidates to treat autoimmune diseases. , inflammatory, metabolic and others.

Mr. Smither most recently served as Chief Financial Officer of Arcutis Biotherapeutics, Inc. Prior to Arcutis, Mr. Smither was Chief Financial Officer of Sienna Biopharmaceuticals. Prior to joining Sienna Biopharmaceuticals, Mr. Smither was Acting Chief Financial Officer of Kite Pharma during its integration with Gilead, and prior to that, he was Chief Financial Officer at Unity Biotechnology. Previously, he served as Chief Financial Officer of Kythera Biopharmaceuticals, Inc. until its acquisition by Allergan for $2.1 billion. Mr. Smither has also held various positions at Amgen, including Vice President of Finance and Administration for Amgen’s European Division, Chief Internal Auditor and Executive Director of Corporate Accounting. Prior to joining Amgen, he was an audit partner at Ernst & Young LLP, an accounting firm. He also served on the board of directors and chair of the audit committee of Achaogen, Inc., and currently serves on the board of directors and chair of the audit committee of eFFECTOR Therapeutics.

Mr. Smither holds a Bachelor of Science in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.

About AMT-101
AMT-101 is a novel GI-selective oral fusion of hIL-10 and AMT’s proprietary carrier molecule, currently in development in four Phase 2 clinical trials in inflammatory bowel disease and rheumatoid arthritis. AMT-101 is designed to cross the intestinal epithelial barrier (IE) with limited entry into the bloodstream, thereby concentrating hIL-10 to the primary site of inflammation for UC and potentially avoiding the side effects seen with systemic administration. By design, AMT-101 is actively transported across the IE barrier into gastrointestinal tissue, the primary site of inflammation in UC.

About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary technology platform to design and develop a portfolio of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cell trafficking pathways to facilitate the active transport of various therapeutic modalities across the intestinal epithelial barrier (EI). Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-tailored oral forms that are designed to target local intestinal tissues or enter the systemic circulation to precisely address relevant disease pathophysiology.

AMT’s corporate headquarters, in-house GMP manufacturing and laboratory facilities are located in South San Francisco, CA. For more information on AMT, please visit

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements relating to AMT’s plans, expectations, forecasts and future events. These forward-looking statements include, but are not limited to, the potential and expectations regarding AMT’s technology platform and AMT’s internal manufacturing capabilities, statements regarding the optimization or expansion of our product development or the design of future clinical trials, statements regarding the potential of AMT-101, AMT-126, AMT’s respiratory vector technology, or regarding clinical trials of AMT-101 and AMT-126, including timing of reading data from these trials and program updates, milestones for these trials and our ability to replicate past clinical development strategies, statements regarding the potential AMT’s product candidates to treat or provide clinically meaningful results for certain medical conditions or diseases, and assumptions regarding the biological mode of action of our product candidates and the potential for avoid side effects with our product candidates. In some cases, you can identify forward-looking statements by words such as “believe”, “estimate”, “intend”, “may”, “plan”, “potentially”, “will”, “will”. expect”, “allow” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual events, trends or results could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements depending on a variety of factors. Information regarding the foregoing and other risks may be found in the section entitled “Risk Factors” in AMT’s annual and quarterly reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission ( the “SEC”), and AMT’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and AMT undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.

Contact with Investor Relations:
Andrew Chang
Head, Investor Relations and Corporate Communications

Media contacts:
Alexandra Santos
Wheelhouse Life Science Advisors

Aljanae Reynolds
Wheelhouse Life Science Advisors

Comments are closed.